Table 5.
Clinical systematic review data for the final shortlisted drugs: number of publications (including interventional and observational studies) and participants according to type of disease
| Drug | Number of publications | Number of participants | ||||||||||
| MND | AD | HD | MS | PD | Total | MND | AD | HD | MS | PD | Total | |
| Acetyl-L-carnitine | 0 | 9 | 1 | 0 | 0 | 10 | 0 | 1224 | 10 | 0 | 0 | 1234 |
| Ciclosporin | 2 | 0 | 0 | 7 | 0 | 9 | 110 | 0 | 0 | 1092 | 0 | 1202 |
| Fluoxetine | 0 | 0 | 1 | 2 | 3 | 6 | 0 | 0 | 30 | 51 | 32 | 113 |
| Melatonin | 1 | 4 | 0 | 0 | 3 | 8 | 3 | 273 | 0 | 0 | 64 | 340 |
| Memantine | 1 | 32 | 2 | 1 | 15 | 51 | 63 | 11 912 | 39 | 116 | 809 | 12 939 |
| N-acetyl cysteine | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 47 | 0 | 0 | 0 | 47 |
| Simvastatin | 0 | 3 | 0 | 1 | 1 | 5 | 0 | 469 | 0 | 307 | 12 | 788 |
AD, Alzheimer’s disease; HD, Huntington’s disease; MND, motor neuron disease; MS, multiple sclerosis; PD, Parkinson’s disease.